OncoMatch/Clinical Trials/NCT04951622
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Is NCT04951622 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Nipocalimab and Nipocalimab SC-LIV for myasthenia gravis.
Treatment: Nipocalimab · Nipocalimab SC-LIV — The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage MGFA CLASS IIA, MGFA CLASS IIB, MGFA CLASS IIIA, MGFA CLASS IIIB, MGFA CLASS IVA, MGFA CLASS IVB
Excluded: Stage MGFA CLASS I, MGFA CLASS V
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Neuromuscular Research Center and Clinic · Paradise Valley, Arizona
- HonorHealth Neurology · Scottsdale, Arizona
- University of Southern California · Los Angeles, California
- Stanford University · Palo Alto, California
- Care Access Research · Pasadena, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify